Add this topic to your myFT Digest for news straight to your inbox
Research by Which? reveals huge disparity between the best and the worst
Large study further boosts fast-evolving efforts to predict and prevent neurogenerative diseases
Cases connected to growth hormone extracted from cadavers show disease’s parallels with CJD brain disorder
Swedish trial finds ‘high accuracy’ in identifying protein associated with toxic build-up in the brain
Boom in asset prices and increased prevalence of dementia drive costly family squabbles over wills
Further research on its underlying causes and preventive action is essential
Emerging research is challenging a widely held belief that new cases of the condition will rise exponentially as people live longer
Pioneering medicines developed by Eisai and Eli Lilly shown to be more effective when taken earlier
AstronauTx’s financing is step towards helping millions of people suffering from disease
Promising trial results will not end scientific debate over the disease, but they further validate pharmaceutical research
Dementia experts hail ‘watershed moment’ after trial results for donanemab antibody treatment
Move by Food and Drug Administration paves way for millions of Americans to access medicine
A decade ago a large part of Big Pharma gave up on one of humanity’s cruellest diseases. But then a new treatment showed promise
Governments have promised to tackle the crisis for 25 years, but it’s never an election winner
Alzheimer’s advocates call for ambitious declaration to match the scope of commitments made 10 years ago
In clinical trials, the medications slowed the progress of the degenerative disease that affects 50mn worldwide
Clinical study results could boost patient access to new class of treatment
With an ageing global population, cases of the disease continue to drastically rise. Two timely and insightful books offer help on how to support the millions of new patients
Money problems experienced by elderly customers can be red flags for families and institutions alike
For all its landmark status, lecanemab may end up representing a triumph of hope over evidence
Committees cite inappropriate collaboration between FDA and drugmaker
Lars Lannfelt had a key role in developing a drug that has shown some promise in tackling Alzheimer’s
Dementia drug development, diagnostics and delivery still require much more investment
Japanese company refuses to rule out possibility treatment contributed to brain bleeds
Shares fall 11% following two patient deaths in trials of lecanemab
UK Edition
